前列腺影像质量评分系统第二版(PI-QUAL V2)的多读者评估及其临床应用
该回顾性研究纳入581例2023年1月至12月间接受前列腺MRI且有明确病理报告的患者,由4名放射科医师独立进行PI-QUAL V2评分,其中1名医师3个月后再次评分。结果显示T2WI、DWI和PI-QUAL V2的读者间一致性为中等,DCE为高度;不同PI-QUAL V2评分间对临床显著前列腺癌的总体诊断性能无显著差异(AUC 0.741-0.844)。
要点
- PI-QUAL V2在T2WI、DWI和总体评分上读者间一致性为中等,DCE为高度。
- 随着图像质量改善,PI-RADS 3分类比例逐渐降低,PI-QUAL 1与3间差异有统计学意义(p < 0.001)。
- 无论以PI-RADS ≥ 3还是≥ 4为可疑癌症阈值,不同PI-QUAL V2评分间对csPCa的总体诊断性能无显著差异(AUC 0.741-0.844)。
核心结论
- PI-QUAL V2在读者间可重复性和放射科医师MRI诊断方面发挥积极作用;但其对临床显著前列腺癌总体诊断的价值有限,未来可能需要更大样本量的进一步探索。
研究设计与样本
- 回顾性研究,纳入581例接受前列腺MRI检查且有明确病理报告的患者,病理标本评估以ISUP Grade Group ≥ 2定义为临床显著前列腺癌(csPCa),由4名放射科医师独立进行PI-QUAL V2评分,其中1名读者间隔3个月后再次评分。
关键影像表现/征象
- T2WI、DWI和PI-QUAL V2的读者间一致性为中等,DCE为高度。
- 在PI-RADS V2.1分类任务中,PI-RADS 3的比例随图像质量改善而逐渐降低,PI-QUAL 1与3之间差异有统计学意义(p < 0.001)。
诊断标准与关键数值
- 以ISUP Grade Group ≥ 2定义为临床显著前列腺癌(csPCa)。
- 采用Cohen's Kappa和Fleiss' Kappa评估读者间一致性,采用受试者工作特征曲线下面积(AUC-ROC)比较诊断性能,p < 0.05认为差异有统计学意义。
- 无论以PI-RADS ≥ 3还是≥ 4作为「可疑癌症」阈值,不同PI-QUAL V2评分间对csPCa的总体诊断性能无显著差异(AUC 0.741-0.844)。
临床应用与阅片要点
- PI-QUAL V2在简化评分系统的同时保留了较高的读者间一致性。
- 次优的PI-QUAL V2评分可能削弱放射科医师对图像解读的信心,导致临床显著前列腺癌检出率降低。
局限性
- 原文指出PI-QUAL V2对临床显著前列腺癌总体诊断的价值有限,未来可能需要更大样本量的进一步探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The objectives of this study were: (1) to investigate the consistency of PI-QUAL V2 and (2) to observe the impact of PI-QUAL V2 on the diagnostic performance for csPCa.
METHODS: This retrospective study included 581 patients who underwent prostate MRI exams and had definitive pathological reports between January and December 2023. All histopathological specimens were evaluated, and an ISUP Grade Group ≥ 2 was considered as csPCa. Four radiologists independently assigned PI-QUAL V2 scores to each patient, with one of the readers re-scoring after a three-month interval. Cohen's and Fleiss' Kappa were used to determine inter-reader agreement, and the area under the receiver operating characteristic curve (AUC-ROC) was used to compare diagnostic performance. A p < 0.05 was considered statistically significant.
RESULTS: The study comprised 581 individuals (median [IQR] age, 70 [66-75] years). The consistency was moderate for T2WI, DWI, and PI-QUAL V2, and substantial for DCE. For PI-RADS V2.1 categorization tasks, the proportion of PI-RADS 3 gradually decreased with improving image quality, and a statistical difference was found between PI-QUAL 1 and 3 (p < 0.001). However, regardless of whether PI-RADS ≥ 3 or ≥ 4 was used as the "suspicious for cancer" threshold, there was no significant difference in overall diagnostic performance for csPCa among different PI-QUAL V2 scores (AUC 0.741-0.844).
CONCLUSION: PI-QUAL V2 plays a positive role in inter-reader reproducibility and radiologists' MRI diagnosis. Regarding the limited value of PI-QUAL V2 in the overall diagnosis of csPCa, further exploration with larger sample sizes and studies may be needed in the future.
KEY POINTS: Question PI-QUAL V2 has overcome the limitations of V1, but its clinical application status remains uncertain. Findings PI-QUAL V2 exhibits a favorable impact on inter-reader reproducibility and radiologists' MRI diagnosis, albeit its overall impact on diagnosing clinically significant prostate cancer remains limited. Clinical relevance While simplifying the scoring system, PI-QUAL V2 retains high inter-reader agreement. A suboptimal PI-QUAL V2 score may undermine radiologists' confidence in image interpretation, resulting in a decreased detection rate of clinically significant prostate cancer.
引用
- Cheng Y, Shen L, Liao Q, et al. Multi-reader evaluation of the prostate imaging quality score system version 2 (PI-QUAL V2) and its clinical application. Eur Radiol. 2025. PMID: 40377676. doi:10.1007/s00330-025-11667-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。